Orchestrating the immune Response
TO Defeat Cancer & Infectious Diseases
Engineering precision immunity
Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer and infectious diseases with potent lymph node targeted immunotherapies and vaccines. Elicio’s Amphiphile platform combines expertise in materials science and immunology to develop novel immunotherapies and vaccines, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.
Lymph nodes:
where the immune response is orchestrated
Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, resulting in tumor or pathogen targeted immunity, including potent T cell and humoral responses. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in early 2021.
NEXT-GENERATION IMMUNO-ONCOLOGY PLATFORM
Our programs
Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2021. This program consists of an Amphiphile vaccine combined with Elicio’s universal AMP CpG adjuvant (ELI-004) with the potential to elicit powerful immune responses against the seven key KRAS mutations, found in 25% of all solid tumors, including 90% of pancreatic cancers, and 40% of colorectal cancers.
Latest News
September 20, 2022 ||
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines
Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations » Read more
September 7, 2022 ||
Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine Against SARS-CoV-2
Data published in bioRxiv shows ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates (NHPs) Prime-boost administration of ELI-005 induced potent Spike receptor binding domain (RBD)-specific effector cytokine-producing T cell responses in mouse and NHP peripheral blood showing cross-reactivity against variants […] » Read more
Orchestrating the immune system for precision immunity — Download this article to see how Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.
A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2 Download this presentation